Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 

Estradiol Transdermal System 0.06MG/24HR 4 Patch By Alvogen Inc.

Image 0 of Estradiol Transdermal System 0.06MG/24HR 4 Patch By Alvogen Inc.

Estradiol Transdermal System 0.06MG/24HR 4 Patch By Alvogen Inc.


Estradiol Transdermal System 0.06MG/24HR 4 Patch By Alvogen Inc. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXB10101634/RXD4544904/RXa207142/RXA320167
Size : 4
Selling UoM : EA
NDC: 47781-0207-04
UPC Barcode : 347781207045
Supplier: 0050001637 ALVOGEN INC.
Supplier Material : 020704
Generic Code : 052830 ESTRADIOL TRANSDERM PATCH TDWK 0.06MG/24
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals

Have a question?


Product Description.:

Climara?, estradiol transdermal system, is designed to release estradiol continuously upon application to intact skin. Six (6.5, 9.375, 12.5, 15, 18.75 and 25 cm?) systems are available to provide nominal in vivo delivery of 0.025, 0.0375, 0.05, 0.06, 0.075 or 0.1 mg respectively of estradiol per day. The period of use is 7 days. Each system has a contact surface area of either 6.5, 9.375, 12.5, 15, 18.75 or 25 cm?, and contains 2, 2.85, 3.8, 4.55, 5.7 or 7.6 mg of estradiol USP respectively. The composition of the systems per unit area is identical. Estradiol USP is a white, crystalline powder, chemically described as estra-1,3,5(10)-triene-3, 17β-diol.

The active component of the system is estradiol. The remaining components of the system (acrylate copolymer adhesive, fatty acid esters, and polyethylene backing) are pharmacologically inactive.


Climara is indicated in the:

1. Treatment of moderate to severe vasomotor symptoms associated with the menopause.
2. Treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with the menopause. When prescribing solely for the treatment of symptoms of vulvar and vaginal atrophy, topical vaginal products should be considered.
3. Treatment of hypoestrogenism due to hypogonadism, castration or primary ovarian failure.
4. Prevention of postmenopausal osteoporosis. When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medications should be carefully considered.

The mainstays for decreasing the risk of postmenopausal osteoporosis are weight bearing exercise, adequate calcium and vitamin D intake, and when indicated, pharmacologic therapy. Postmenopausal women require an average of 1500mg/day of elemental calcium. Therefore, when not contraindicated, calcium supplementation may be helpful for women with suboptimal dietary intake. Vitamin D supplementation of 400-800 IU/day may also be required to ensure adequate daily intake in postmenopausal women.



Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The adverse reaction information from clinical trials does, however, provide a basis for identifying the adverse events that appear to be related to drug use and for approximating rates.